Breast CancerPhase 3NCT00775645
S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo
A Phase 3 study testing acetyl-L-carnitine hydrochloride in people with Breast Cancer and Chemotherapeutic Agent Toxicity, run by SWOG Cancer Research Network at 295 sites in United States.
Trial summary
RATIONALE: Acetyl-L-carnitine may prevent or lessen neuropathy caused by chemotherapy. It is not yet known whether acetyl-L-carnitine is more effective than a placebo in preventing neuropathy caused by chemotherapy. Read more about this study
- Who is it for?
- Ages 18 to 120 years, women only
- Conditions the study is for
- Breast Cancer, Chemotherapeutic Agent Toxicity, Fatigue
- What is being tested?
- acetyl-L-carnitine hydrochloride
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 437 participants
- Where
- 295 sitesUnited States
- Study dates
- Sep 2009to Jun 2013
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- Women only
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically confirmed primary invasive adenocarcinoma of the breast
- Stage I-III disease
- No metastatic disease
- Must have undergone modified radical mastectomy or breast-sparing surgery
- Planning to receive one of the following standard taxane-based systemic chemotherapy regimens as adjuvant therapy for breast cancer:
- Paclitaxel 80 mg/m² weekly for 12 weeks
- Paclitaxel 175 mg/m² every other week for 4 courses (8 weeks)
- Paclitaxel 175 mg/m² every other week for 6 courses (12 weeks)
- Docetaxel 75 mg/m² every 3 weeks for 4 courses (12 weeks)
- Docetaxel 75 mg/m² every 3 weeks for 6 courses (18 weeks)
- No history of neuropathy
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Menopausal status not specified
- Zubrod performance status 0-2
- Serum creatinine ≤ 2.5 times upper limit of normal
- Not pregnant or nursing
- Fertile patients must use effective contraception
- Able to complete questionnaires in English or Spanish
- Willing to submit blood samples for DNA extraction, genotyping analysis, and nerve growth factor studies
- No history of diabetes
- No history of seizure disorder
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, ductal carcinoma in situ, or adequately treated stage I or stage II malignancy from which the patient is currently in complete remission
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Recovered from prior breast surgery
- Prior neoadjuvant or adjuvant chemotherapy allowed
- No prior taxane therapy
- No prior biologic therapy for treatment of breast cancer
- No concurrent vitamin E, glutamine, gabapentin, nortriptyline, amitriptyline, or duloxetine hydrochloride
- Multivitamins containing vitamin E allowed provided vitamin E dose is < 1,000 IU
- No concurrent anti-seizure medications
- Concurrent hormonal therapy allowed
- Concurrent biologic therapy allowed (e.g., Herceptin)
- Concurrent participation in another therapeutic clinical trial allowed
Trial locations and contacts
295 sites in 1 country.
295 sites in 1 country
United States295 sites
Kapiolani Medical Center at Pali Momi
‘Aiea, Hawaii, 96701
McDowell Cancer Center at Akron General Medical Center
Akron, Ohio, 44307
San Luis Valley Regional Medical Center
Alamosa, Colorado, 81101
Lovelace Medical Center - Downtown
Albuquerque, New Mexico, 87102
Presbyterian Cancer Treatment Center at Presbyterian Kaseman Hospital
Albuquerque, New Mexico, 87110
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87131-5636
Northeast Louisiana Cancer Institute at St. Francis Medical Center
Alexandria, Louisiana, 71301
Tulane Cancer Center Office of Clinical Research
Alexandria, Louisiana, 71315-3198
Saint Anthony's Hospital at Saint Anthony's Health Center
Alton, Illinois, 62002
Alaska Regional Hospital Cancer Center
Anchorage, Alaska, 99508
Providence Cancer Center
Anchorage, Alaska, 99508
AnMed Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Cancer Center
Ann Arbor, Michigan, 48106-0995
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
Kaiser Permanente - Deer Valley
Antioch, California, 94531
Cancer Care at Our Lady of Bellefonte Hospital
Ashland, Kentucky, 41101
Piedmont Hospital
Atlanta, Georgia, 30309
Northside Hospital Cancer Center
Atlanta, Georgia, 30342-1611
Saint Joseph's Hospital of Atlanta
Atlanta, Georgia, 30342-1701
CCOP - Atlanta Regional
Atlanta, Georgia, 30342
University of Colorado Cancer Center at UC Health Sciences Center
Aurora, Colorado, 80045
WellStar Cobb Hospital
Austell, Georgia, 30106
Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
Baltimore, Maryland, 21215
Mary Bird Perkins Cancer Center - Baton Rouge
Baton Rouge, Louisiana, 70809
Battle Creek Health System Cancer Care Center
Battle Creek, Michigan, 49017
Bay Regional Medical Center
Bay City, Michigan, 48708
Cleveland Clinic Beachwood Family Health and Surgery Center
Beachwood, Ohio, 44122
St. Francis Hospital and Health Centers - Beech Grove Campus
Beech Grove, Indiana, 46107
Mary Rutan Hospital
Bellefontaine, Ohio, 43311
St. Joseph Cancer Center
Bellingham, Washington, 98225
St. Charles Medical Center - Bend
Bend, Oregon, 97701
Alta Bates Summit Comprehensive Cancer Center
Berkeley, California, 94704
Mecosta County Medical Center
Big Rapids, Michigan, 49307
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
St. Vincent Healthcare Cancer Care Services
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59102
Billings Clinic - Downtown
Billings, Montana, 59107-7000
Boston University Cancer Research Center
Boston, Massachusetts, 02118
Bozeman Deaconess Cancer Center
Bozeman, Montana, 59715
Skaggs Cancer Center at Skaggs Regional Medical Center
Branson, Missouri, 65616
Olympic Hematology and Oncology
Bremerton, Washington, 98310
Caritas St. Elizabeth's Medical Center
Brighton, Massachusetts, 02135-2997
Peninsula Medical Center
Burlingame, California, 94010
St. James Healthcare Cancer Care
Butte, Montana, 59701
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Rocky Mountain Oncology
Casper, Wyoming, 82609
East Bay Radiation Oncology Center
Castro Valley, California, 94546
Eden Medical Center
Castro Valley, California, 94546
Valley Medical Oncology Consultants - Castro Valley
Castro Valley, California, 94546
Providence Centralia Hospital
Centralia, Washington, 98531-9027
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, 45267
Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio, 44111
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
John B. Amos Cancer Center
Columbus, Georgia, 31904
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
CCOP - Columbus
Columbus, Ohio, 43215
Grant Medical Center Cancer Care
Columbus, Ohio, 43215
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Bay Area Hospital
Coos Bay, Oregon, 97420
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Genesis Medical Center - West Campus
Davenport, Iowa, 52804
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
CCOP - Dayton
Dayton, Ohio, 45420
Oakwood Cancer Center at Oakwood Hospital and Medical Center
Dearborn, Michigan, 48123-2500
Charles B. Eberhart Cancer Center at DeKalb Medical Center
Decatur, Georgia, 30033
Cancer Care Center of Decatur
Decatur, Illinois, 62526
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
Grady Memorial Hospital
Delaware, Ohio, 43015
Denver Health Medical Center
Denver, Colorado, 80204
Kaiser Permanente - Denver
Denver, Colorado, 80205
Josephine Ford Cancer Center at Henry Ford Hospital
Detroit, Michigan, 48202
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Cancer Centers of the Carolinas - Easley
Easley, South Carolina, 29640
Shaw Regional Cancer Center
Edwards, Colorado, 81632
Crossroads Cancer Center
Effingham, Illinois, 62401
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
Fairbanks, Alaska, 99701
St. Francis Hospital
Federal Way, Washington, 98003
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
Great Lakes Cancer Institute at McLaren Regional Medical Center
Flint, Michigan, 48532
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Kaiser Permanente - Fremont
Fremont, California, 94538
Valley Medical Oncology
Fremont, California, 94538
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
CaroMont Cancer Center at Gaston Memorial Hospital
Gastonia, North Carolina, 28053
Glendale Memorial Hospital Comprehensive Cancer Center
Glendale, California, 91204
Valley View Hospital Cancer Center
Glenwood Springs, Colorado, 81601
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
Grand Junction, Colorado, 81502
Butterworth Hospital at Spectrum Health
Grand Rapids, Michigan, 49503
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Health Care
Grand Rapids, Michigan, 49503
Big Sky Oncology
Great Falls, Montana, 59405-5309
Great Falls Clinic - Main Facility
Great Falls, Montana, 59405
Sletten Cancer Institute at Benefis Healthcare
Great Falls, Montana, 59405
Study site
Great Falls, Montana, 59405
Wayne Hospital
Greenville, Ohio, 45331
Bon Secours St. Francis Health System
Greenville, South Carolina, 29601
Cancer Centers of the Carolinas - Faris Road
Greenville, South Carolina, 29605
Cancer Centers of the Carolinas - Grove Commons
Greenville, South Carolina, 29605
Greenville Hospital Cancer Center
Greenville, South Carolina, 29605
CCOP - Greenville
Greenville, South Carolina, 29615
Self Regional Cancer Center at Self Regional Medical Center
Greenwood, South Carolina, 29646
Cancer Centers of the Carolinas - Greer Medical Oncology
Greer, South Carolina, 29650
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Van Elslander Cancer Center at St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, 48236
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
Hartford, Connecticut, 06105
Northern Montana Hospital
Havre, Montana, 59501
Kaiser Permanente Medical Center - Hayward
Hayward, California, 94545
St. Peter's Hospital
Helena, Montana, 59601
Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
High Point Regional Hospital
High Point, North Carolina, 27261
Cancer Research Center of Hawaii
Honolulu, Hawaii, 96813
OnCare Hawaii, Incorporated - Lusitana
Honolulu, Hawaii, 96813
Queen's Cancer Institute at Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital, Incorporated
Honolulu, Hawaii, 96813
Hawaii Medical Center - East
Honolulu, Hawaii, 96817
OnCare Hawaii, Incorporated - Kuakini
Honolulu, Hawaii, 96817
Kaiser Permanente - Moanalua Medical Center and Clinic
Honolulu, Hawaii, 96819
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
Tripler Army Medical Center
Honolulu, Hawaii, 96859
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Cleveland Clinic Cancer Center
Independence, Ohio, 44131
Foote Memorial Hospital
Jackson, Michigan, 49201
University of Mississippi Cancer Clinic
Jackson, Mississippi, 39216
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology at KRMC
Kalispell, Montana, 59901
Columbia Basin Hematology
Kennewick, Washington, 99336
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Cascade Cancer Center at Evergreen Hospital Medical Center
Kirkland, Washington, 98033
Kaiser Permanente - Lafayette
Lafayette, Colorado, 80026
Fairfield Medical Center
Lancaster, Ohio, 43130
Breslin Cancer Center at Ingham Regional Medical Center
Lansing, Michigan, 48910
Sparrow Regional Cancer Center
Lansing, Michigan, 48912-1811
Lapeer Regional Hospital
Lapeer, Michigan, 48446
University of New Mexico Cancer Center - South
Las Cruces, New Mexico, 88011
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
CCOP - Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Gwinnett Medical Center
Lawrenceville, Georgia, 30045
Cancer Center of Kansas, PA - Liberal
Liberal, Kansas, 67905
St. Mary Mercy Hospital
Livonia, Michigan, 48154
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90089-9181
MedCentral - Mansfield Hospital
Mansfield, Ohio, 44903
Kennestone Cancer Center at Wellstar Kennestone Hospital
Marietta, Georgia, 30060
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Contra Costa Regional Medical Center
Martinez, California, 94553-3156
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
Marysville, California, 95901
Hillcrest Cancer Center at Hillcrest Hospital
Mayfield Heights, Ohio, 44124
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153
Tucker Center for Cancer Care at Orange Regional Medical Center
Middletown, New York, 10940-4199
MidMichigan Medical Center - Midland
Midland, Michigan, 48670
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Guardian Oncology and Center for Wellness
Missoula, Montana, 59804
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
Providence Cancer Center at Providence Hospital
Mobile, Alabama, 36608
Louisiana State University Health Sciences Center - Monroe
Monroe, Louisiana, 71210
Montrose Memorial Hospital Cancer Center
Montrose, Colorado, 81401
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Knox Community Hospital
Mount Vernon, Ohio, 43050
Skagit Valley Hospital Cancer Care Center
Mount Vernon, Washington, 98273
El Camino Hospital Cancer Center
Mountain View, California, 94040
Mercy General Health Partners
Muskegon, Michigan, 49443
Edward Hospital Cancer Center
Naperville, Illinois, 60540
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112
Medical Center of Louisiana - New Orleans
New Orleans, Louisiana, 70112
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
New York, New York, 10032
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Cancer Center of Kansas, PA - Newton
Newton, Kansas, 67114
Highland General Hospital
Oakland, California, 94602
Alta Bates Summit Medical Center - Summit Campus
Oakland, California, 94609
Bay Area Breast Surgeons, Incorporated
Oakland, California, 94609
CCOP - Bay Area Tumor Institute
Oakland, California, 94609
Larry G Strieff MD Medical Corporation
Oakland, California, 94609
Tom K Lee, Incorporated
Oakland, California, 94609
Kaiser Permanente Medical Center - Oakland
Oakland, California, 94611
Providence St. Peter Hospital Regional Cancer Center
Olympia, Washington, 98506-5166
Cancer Center of Kansas, PA - Parsons
Parsons, Kansas, 67357
Regional Cancer Center at Singing River Hospital
Pascagoula, Mississippi, 39581
Valley Care Medical Center
Pleasanton, California, 94588
Valley Medical Oncology Consultants - Pleasanton
Pleasanton, California, 94588
St. Joseph Mercy Oakland
Pontiac, Michigan, 48341-2985
Mercy Regional Cancer Center at Mercy Hospital
Port Huron, Michigan, 48060
Legacy Good Samaritan Hospital & Comprehensive Cancer Center
Portland, Oregon, 97210
Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, 97213-2967
Adventist Medical Center
Portland, Oregon, 97216
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Kaiser Permanente Health Care - Portland
Portland, Oregon, 97227
Legacy Emanuel Hospital and Health Center and Children's Hospital
Portland, Oregon, 97227
Northwest Cancer Specialists at Rose Quarter Cancer Center
Portland, Oregon, 97227
Harrison Poulsbo Hematology and Onocology
Poulsbo, Washington, 98370
Cancer Center of Kansas, PA - Pratt
Pratt, Kansas, 67124
Good Samaritan Cancer Center
Puyallup, Washington, 98372
Kaiser Permanente Medical Center - Redwood City
Redwood City, California, 94063
Kaiser Permanente Medical Center - Richmond
Richmond, California, 94801
Reid Hospital & Health Care Services
Richmond, Indiana, 47374
Southern Regional Medical Center
Riverdale, Georgia, 30274-2600
Harbin Clinic Cancer Center - Medical Oncology
Rome, Georgia, 30165
Kaiser Permanente Medical Center - Roseville
Roseville, California, 95661
Sutter Cancer Center at Roseville Medical Center
Roseville, California, 95661
William Beaumont Hospital - Royal Oak Campus
Royal Oak, Michigan, 48073
Rutherford Hospital
Rutherfordton, North Carolina, 28139
Sutter Cancer Center
Sacramento, California, 95816
University of California Davis Cancer Center
Sacramento, California, 95817
South Sacramento Kaiser-Permanente Medical Center
Sacramento, California, 95823
Kaiser Permanente Medical Center - Sacramento
Sacramento, California, 95825
Seton Cancer Institute at Saint Mary's - Saginaw
Saginaw, Michigan, 48601
Salem Hospital Regional Cancer Care Services
Salem, Oregon, 97309-5014
Cancer Center of Kansas, PA - Salina
Salina, Kansas, 67401
Kaiser Permanente Medical Center - San Francisco Geary Campus
San Francisco, California, 94115
California Pacific Medical Center - California Campus
San Francisco, California, 94118
Kaiser Permanente Medical Center - Santa Teresa
San Jose, California, 95119
Doctors Medical Center - San Pablo Campus
San Pablo, California, 94806
Kaiser Foundation Hospital - San Rafael
San Rafael, California, 94903
Sutter Health - Western Division Cancer Research Group
San Rafael, California, 94903
Kaiser Permanente Medical Center - Santa Clara Kiely Campus
Santa Clara, California, 95051
Kaiser Permanente Medical Center - Santa Rosa
Santa Rosa, California, 95403
Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler
Savannah, Georgia, 31405
CCOP - Virginia Mason Research Center
Seattle, Washington, 98101
Harborview Medical Center
Seattle, Washington, 98104
Minor and James Medical, PLLC
Seattle, Washington, 98104
Pacific Medical Center
Seattle, Washington, 98104
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109
Group Health Central Hospital
Seattle, Washington, 98112
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
Seattle, Washington, 98122-4307
Polyclinic First Hill
Seattle, Washington, 98122
University Cancer Center at University of Washington Medical Center
Seattle, Washington, 98195
Cancer Centers of the Carolinas - Seneca
Seneca, South Carolina, 29672
Welch Cancer Center at Sheridan Memorial Hospital
Sheridan, Wyoming, 82801
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
Shreveport, Louisiana, 71130-3932
Kaiser Permanente Medical Center - South San Francisco
South San Francisco, California, 94080
Providence Cancer Institute at Providence Hospital - Southfield Campus
Southfield, Michigan, 48075
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
Spartanburg, South Carolina, 29303
Cancer Centers of the Carolinas - Spartanburg
Spartanburg, South Carolina, 29307
Cancer Care Northwest - Spokane South
Spokane, Washington, 99202
Evergreen Hematology and Oncology, PS
Spokane, Washington, 99218
Regional Cancer Center at Memorial Medical Center
Springfield, Illinois, 62781-0001
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65802
St. John's Regional Health Center
Springfield, Missouri, 65804
Hulston Cancer Center at Cox Medical Center South
Springfield, Missouri, 65807
Community Hospital of Springfield and Clark County
Springfield, Ohio, 45505
Midwest Hematology Oncology Group, Incorporated
St Louis, Missouri, 63109
CCOP - St. Louis-Cape Girardeau
St Louis, Missouri, 63141
David C. Pratt Cancer Center at St. John's Mercy
St Louis, Missouri, 63141
Iredell Memorial Hospital
Statesville, North Carolina, 28677
Kaiser Permanente Medical Facility - Stockton
Stockton, California, 95210
Franciscan Cancer Center at St. Joseph Medical Center
Tacoma, Washington, 98405-3004
Allenmore Hospital
Tacoma, Washington, 98405
CCOP - Northwest
Tacoma, Washington, 98405
MultiCare Regional Cancer Center at Tacoma General Hospital
Tacoma, Washington, 98405
St. Clare Hospital
Tacoma, Washington, 98499
Cotton-O'Neil Cancer Center
Topeka, Kansas, 66606
Munson Medical Center
Traverse City, Michigan, 49684
UVMC Cancer Care Center at Upper Valley Medical Center
Troy, Ohio, 45373-1300
Tahoe Forest Cancer Center
Truckee, California, 96161
Legacy Meridian Park Hospital
Tualatin, Oregon, 97062
Kaiser Permanente Medical Center - Vacaville
Vacaville, California, 95688
Pearlman Comprehensive Cancer Center at South Georgia Medical Center
Valdosta, Georgia, 31603
Kaiser Permanente Medical Center - Vallejo
Vallejo, California, 94589
Sutter Solano Medical Center
Vallejo, California, 94589
Southwest Washington Medical Center Cancer Center
Vancouver, Washington, 98668
Legacy Salmon Creek Medical Center
Vancouver, Washington, 98686
Pacific Cancer Institute - Maui
Wailuku, Hawaii, 96793
Kaiser Permanente Medical Center - Walnut Creek
Walnut Creek, California, 94596
St. John Macomb Hospital
Warren, Michigan, 48093
Cancer Center of Kansas, PA - Wellington
Wellington, Kansas, 67152
Wenatchee Valley Medical Center
Wenatchee, Washington, 98801-2028
Mount Carmel St. Ann's Cancer Center
Westerville, Ohio, 43081
Cancer Center of Kansas, PA - Medical Arts Tower
Wichita, Kansas, 67208
Cancer Center of Kansas, PA - Wichita
Wichita, Kansas, 67214
CCOP - Wichita
Wichita, Kansas, 67214
Via Christi Cancer Center at Via Christi Regional Medical Center
Wichita, Kansas, 67214
Clinton Memorial Hospital
Wilmington, Ohio, 45177
Cancer Center of Kansas, PA - Winfield
Winfield, Kansas, 67156
Cleveland Clinic - Wooster
Wooster, Ohio, 44691
United States Air Force Medical Center - Wright-Patterson
Wright-Patterson Air Force Base, Ohio, 45433-5529
Metro Health Hospital
Wyoming, Michigan, 49519
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
Xenia, Ohio, 45385
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
Yakima, Washington, 98902
Genesis - Good Samaritan Hospital
Zanesville, Ohio, 43701
About this study
Official title: S0715: Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine (ALC) for the Prevention of Taxane Induced Neuropathy Phase III
RATIONALE: Acetyl-L-carnitine may prevent or lessen neuropathy caused by chemotherapy. It is not yet known whether acetyl-L-carnitine is more effective than a placebo in preventing neuropathy caused by chemotherapy.
PURPOSE: This randomized phase III trial is studying acetyl-L-carnitine to see how well it works compared with a placebo in preventing neuropathy in women with stage I, stage II, or stage III breast cancer undergoing chemotherapy.
Read the detailed description
OBJECTIVES:
Primary
- Compare whether treatment with acetyl-L-carnitine hydrochloride vs placebo prevents symptoms of neuropathy as measured by the 11-item neurotoxicity component of the FACT-Taxane Questionnaire at 12 weeks after study registration in women with stage I, II, or IIIA breast cancer undergoing adjuvant taxane-based chemotherapy.
Secondary
- Compare the functional status of these patients using the Trial Outcome Index from the Functional Assessment of Cancer Therapy (FACT)-Taxane Questionnaire.
- Compare fatigue in these patients using the Function Assessment of Chronic Illness Therapy (FACIT)-Fatigue Symptom Module.
Other
- Compare the proportion of patients experiencing grade 3 or 4 neuropathy.
- Compare serum nerve growth factor levels in these patients.
- Describe the total dose of taxane received and treatment delays, compliance with therapy, and use of concurrent medications, dietary supplements (e.g., glutamine), vitamin E, and complementary and alternative medicines in these patients.
- Explore the relationship between nerve growth factor levels and the degree of neuropathy and functional status in these patients.
- Explore the relationship between genetic markers responsible for taxane metabolism and clearance (e.g., CYP2C8, CYP3A4, CYP3A5, GSTM1, and GSTP1) and the degree of neuropathy in these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to planned adjuvant chemotherapy regimen for breast cancer (paclitaxel weekly for 12 weeks vs paclitaxel biweekly for 4 courses [8 weeks] vs paclitaxel biweekly for 6 courses [12 weeks] vs docetaxel every 3 weeks for 4 courses [12 weeks] vs docetaxel every 3 weeks for 6 courses [18 weeks]) and age (< 60 years vs ≥ 60 years). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral acetyl-L-carnitine hydrochloride 3 times daily for 24 weeks.
- Arm II: Patients receive oral placebo 3 times daily for 24 weeks. Patients complete the FACT-Taxane Trial Outcome Index and the FACIT-Fatigue Symptom Module questionnaires at baseline, at 12, 24, and 36 weeks, and at 1 and 2 years.
Blood samples are collected at baseline and at week 12 for biomarker analysis (nerve growth factor levels) by ELISA, DNA extraction, and genotyping analysis.
- Being tested
- acetyl-L-carnitine hydrochloride, placebo
- Keywords
- neurotoxicity, chemotherapeutic agent toxicity, fatigue, neuropathy, stage IA breast cancer, stage IB breast cancer, stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer
- Medical subject headings
- Breast Neoplasms, Fatigue, Neurotoxicity Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
acetyl-L-carnitine hydrochlorideDietary supplement
Given orally
placeboOther
Given orally
| Study group | Role | What they receive |
|---|---|---|
| Arm I | Experimental | Patients receive oral acetyl-L-carnitine hydrochloride 3 times daily for 24 weeks. Receives: Dietary Supplement: acetyl-L-carnitine hydrochloride |
| Arm II | Placebo comparator | Patients receive oral placebo 3 times daily for 24 weeks. Receives: Other: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
12-week FACT-Taxane Neurotoxicity Model-adjusted Score in ALC and Placebo Groups
Compare whether treatment with acetyl-L-carnitine hydrochloride vs placebo prevents symptoms of neuropathy as measured by the 11-item neurotoxicity (NTX) component of the Functional Assesment of Cancer Therapy (FACT)-Taxane Questionnaire at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate worse CIPN. Total possible range is 0 to 64. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires
Measured: 12 weeks post-registration
Secondary outcomes (2)
12-week FACT-Trial Outcome Index(TOI) Functional Status Model-adjusted Score in ALC and Placebo Groups
Compare FACT-TOI outcome in treatment vs placebo groups at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate worse functional status. Total possible range is 0 to 120. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires
Measured: 12 weeks post-registration
12-week FACIT-fatigue Model-adjusted Score in ALC and Placebo Groups
Compare fatigue outcome between treatment and placebo groups as measured by the 13-item Functional Assessment of Chronic Illness Therapy FACIT-fatigue questionnaire at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate more fatigue. Total possible range is 0 to 52. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires
Measured: 12 weeks post-registration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2008 (estimated)
- Study startSep 2009
- Primary completionJan 2012
- Study completionJun 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 437 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Laurence H. Baker, DO, FACOI, Principal investigator, University of Michigan Rogel Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00775645
- Sponsor's protocol ID
- CDR0000617081
- Other IDs
- S0715, U10CA037429
- Status last verified
- Jun 2017
- First submitted
- 17 Oct 2008
- Last updated
- 14 Aug 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol. 2013 Jul 10;31(20):2627-33. doi: 10.1200/JCO.2012.44.8738. Epub 2013 Jun 3.
PubMed 23733756
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- S0715: Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine (ALC) for the Prevention of Taxane Induced Neuropathy Phase III
- ClinicalTrials.gov ID
- NCT00775645
- Acronym / sponsor ID
- CDR0000617081
- Keywords
- neurotoxicity, chemotherapeutic agent toxicity, fatigue, neuropathy, stage IA breast cancer, stage IB breast cancer, stage II breast cancer, stage IIIA breast cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 437 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Sep 2009
- Primary completion
- Jan 2012 (actual)
- Study completion
- Jun 2013 (actual)
- First posted
- 20 Oct 2008 (estimated)
- Results
- Posted 10 Apr 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Acetyl-L-carnitine may prevent or lessen neuropathy caused by chemotherapy. It is not yet known whether acetyl-L-carnitine is more effective than a placebo in preventing neuropathy caused by chemotherapy.
PURPOSE: This randomized phase III trial is studying acetyl-L-carnitine to see how well it works compared with a placebo in preventing neuropathy in women with stage I, stage II, or stage III breast cancer undergoing chemotherapy.
Detailed description
OBJECTIVES:
Primary
- Compare whether treatment with acetyl-L-carnitine hydrochloride vs placebo prevents symptoms of neuropathy as measured by the 11-item neurotoxicity component of the FACT-Taxane Questionnaire at 12 weeks after study registration in women with stage I, II, or IIIA breast cancer undergoing adjuvant taxane-based chemotherapy.
Secondary
- Compare the functional status of these patients using the Trial Outcome Index from the Functional Assessment of Cancer Therapy (FACT)-Taxane Questionnaire.
- Compare fatigue in these patients using the Function Assessment of Chronic Illness Therapy (FACIT)-Fatigue Symptom Module.
Other
- Compare the proportion of patients experiencing grade 3 or 4 neuropathy.
- Compare serum nerve growth factor levels in these patients.
- Describe the total dose of taxane received and treatment delays, compliance with therapy, and use of concurrent medications, dietary supplements (e.g., glutamine), vitamin E, and complementary and alternative medicines in these patients.
- Explore the relationship between nerve growth factor levels and the degree of neuropathy and functional status in these patients.
- Explore the relationship between genetic markers responsible for taxane metabolism and clearance (e.g., CYP2C8, CYP3A4, CYP3A5, GSTM1, and GSTP1) and the degree of neuropathy in these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to planned adjuvant chemotherapy regimen for breast cancer (paclitaxel weekly for 12 weeks vs paclitaxel biweekly for 4 courses [8 weeks] vs paclitaxel biweekly for 6 courses [12 weeks] vs docetaxel every 3 weeks for 4 courses [12 weeks] vs docetaxel every 3 weeks for 6 courses [18 weeks]) and age (< 60 years vs ≥ 60 years). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral acetyl-L-carnitine hydrochloride 3 times daily for 24 weeks.
- Arm II: Patients receive oral placebo 3 times daily for 24 weeks. Patients complete the FACT-Taxane Trial Outcome Index and the FACIT-Fatigue Symptom Module questionnaires at baseline, at 12, 24, and 36 weeks, and at 1 and 2 years.
Blood samples are collected at baseline and at week 12 for biomarker analysis (nerve growth factor levels) by ELISA, DNA extraction, and genotyping analysis.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm I | Experimental | Dietary Supplement: acetyl-L-carnitine hydrochloridePatients receive oral acetyl-L-carnitine hydrochloride 3 times daily for 24 weeks. |
| Arm II | Placebo comparator | Other: placeboPatients receive oral placebo 3 times daily for 24 weeks. |
Who may qualify
- Ages
- 18 to 120 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| acetyl-L-carnitine hydrochlorideGiven orally | Dietary supplement | Arm I |
| placeboGiven orally | Other | Arm II |
Primary outcome
12-week FACT-Taxane Neurotoxicity Model-adjusted Score in ALC and Placebo Groups
Time frame: 12 weeks post-registration
Compare whether treatment with acetyl-L-carnitine hydrochloride vs placebo prevents symptoms of neuropathy as measured by the 11-item neurotoxicity (NTX) component of the Functional Assesment of Cancer Therapy (FACT)-Taxane Questionnaire at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate worse CIPN. Total possible range is 0 to 64. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires
2 secondary outcomes
12-week FACT-Trial Outcome Index(TOI) Functional Status Model-adjusted Score in ALC and Placebo Groups
Time frame: 12 weeks post-registration
12-week FACIT-fatigue Model-adjusted Score in ALC and Placebo Groups
Time frame: 12 weeks post-registration
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 23733756Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol. 2013 Jul 10;31(20):2627-33. doi: 10.1200/JCO.2012.44.8738. Epub 2013 Jun 3.
- Individual participant dataSharing planned: No
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Laurence H. Baker, DO, FACOI principal investigator
University of Michigan Rogel Cancer Center
295 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing acetyl-L-carnitine hydrochloride in people with Breast Cancer and Chemotherapeutic Agent Toxicity, run by SWOG Cancer Research Network at 295 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 295 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Apr 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
12-week FACT-Taxane Neurotoxicity Model-adjusted Score in ALC and Placebo Groups (time frame: 12 weeks post-registration). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00775645, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2017.